Ethypharm ready to bring to patients world-leading digital therapies for depression and addiction
On April 6, 2021 Ethypharm announced that it has acquired exclusive rights in several European countries for two CE-marked digital therapies, deprexis® and vorvida®, developed by GAIA AG (GAIA), a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area of the Central Nervous System (CNS) where there are significant unmet needs.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm partners with Clever Leaves for medical cannabis products in Germany
On March 17, 2021 Ethypharm signed an exclusive license agreement with Clever Leaves for the distribution and sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. For Ethypharm, this is a further step to become a leading and trusted provider of medical cannabis products in Europe.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website